CORT ALERT: April 21st Deadline in Fraud Class Action!

Overview: Corcept Therapeutics (NASDAQ: CORT) is a biotech company now under legal scrutiny amid a securities fraud class action lawsuit. The April 21, 2026 lead-plaintiff deadline looms for shareholders to join this case (www.globenewswire.com). The complaint alleges that Corcept misled investors about its lead drug candidate relacorilant – concealing the FDA’s repeated warnings about insufficient efficacy data (www.globenewswire.com). When the FDA ultimately declined to approve relacorilant in late 2025, Corcept’s optimistic narrative unraveled and the stock plunged ~50% in a single day (www.globenewswire.com). This report examines Corcept’s fundamentals (dividend policy, leverage, financial health, valuation) and evaluates key risks and red flags, including those highlighted by the class action allegations.

Company Background & Relacorilant Setback

Corcept’s Business: Corcept Therapeutics specializes in drugs that modulate cortisol activity, targeting diseases of hypercortisolism (excess cortisol). Its sole commercial product, Korlym (mifepristone), was approved in 2012 for Cushing’s syndrome (endogenous hypercortisolism) and remains the company’s main revenue source (www.trefis.com). Korlym is an oral cortisol receptor antagonist that helps control the symptoms of Cushing’s syndrome. Corcept has been highly dependent on Korlym, which until recently enjoyed market exclusivity as an orphan drug. The company has pursued new indications and next-generation compounds to diversify its portfolio, chief among them relacorilant – a selective cortisol modulator intended as a safer, more effective follow-on to Korlym.

Relacorilant’s FDA Rejection: Relacorilant was the cornerstone of Corcept’s growth plans. The company announced positive Phase 3 results (the GRACE trial) for relacorilant in treating patients with Cushing’s syndrome, and submitted a New Drug Application (NDA) in late 2024 (www.sec.gov) (www.sec.gov). However, on December 30, 2025, the FDA issued a Complete Response Letter (CRL) declining to approve relacorilant (www.sec.gov). The FDA acknowledged that GRACE met its primary endpoint and that a supportive Phase 3 (GRADIENT) provided confirmatory evidence, but still concluded “additional evidence of efficacy” was required for approval (www.sec.gov). In other words, despite encouraging trial data, regulators weren’t convinced the drug’s benefit–risk profile was favorable without further proof. Corcept disclosed that it is working with the FDA to determine relacorilant’s optimal path forward (likely meaning additional trials or data analyses) (www.sec.gov).

This surprise setback dealt a serious blow to Corcept’s outlook. The stock price plummeted from about $70 on 12/30/25 to ~$35 on 12/31/25 (www.globenewswire.com), erasing nearly half of Corcept’s market capitalization overnight. Analysts noted this “violent repricing” reflected a loss of confidence in Corcept’s future growth, given how heavily its prospects were tied to relacorilant’s anticipated launch (www.trefis.com) (www.trefis.com). The FDA’s rejection not only delays any new revenue from relacorilant, but also prolongs Corcept’s reliance on Korlym (www.trefis.com). It even casts doubt on other pipeline candidates that use a similar mechanism, underscoring the challenge Corcept faces to diversify its product base (www.trefis.com).

Pipeline and R&D Initiatives: Beyond relacorilant, Corcept’s pipeline features several earlier-stage compounds leveraging its core expertise in cortisol modulation. Notably, miricorilant is in Phase 2 testing as a potential treatment for metabolic disorders like non-alcoholic steatohepatitis (NASH/MASH) (www.sec.gov). A Phase 2b trial (MONARCH) in patients with liver fibrosis due to NASH was launched in late 2023, and enrollment is complete (www.sec.gov) – results from this trial (expected in 2024–2025) will signal whether miricorilant can advance to Phase 3. Corcept is also exploring dazucorilant (another cortisol modulator) in neurological conditions: dazucorilant received FDA Fast Track and orphan drug designation for ALS (amyotrophic lateral sclerosis), and Corcept plans to start a pivotal Phase 3 trial in 2026 for this indication (www.sec.gov). Additionally, relacorilant itself is being studied in oncology settings – it holds orphan designation for pancreatic cancer and has been tested in combination therapies for solid tumors (www.sec.gov). While these pipeline programs could create future value, they are all in mid-to-early phases. In the near term, Corcept’s fortunes rest predominantly on Korlym and the outcome of relacorilant’s regulatory saga.

Dividend Policy and Shareholder Returns

No Dividend History: Corcept does not pay dividends and has never declared a cash dividend on its stock (www.sec.gov) (www.sec.gov). The company explicitly states that it “has never paid dividends on our common stock” and does not anticipate doing so in the foreseeable future (www.sec.gov). This is typical for developmental biopharma companies, which tend to reinvest earnings into R&D rather than distribute cash. Investors in CORT should not expect income from dividends; any return is likely to come from stock price appreciation (or lack thereof).

Share Buybacks: Instead of dividends, Corcept has occasionally returned capital to shareholders via stock repurchases. In January 2024, the Board of Directors authorized a stock repurchase program for up to $200 million of common stock (www.sec.gov). Under this program, Corcept bought back approximately 2.6 million shares in open-market transactions during 2025 (www.sec.gov). This followed a sizeable tender offer in 2023 by which Corcept had repurchased shares for about $145 million (indicated by a one-time financing cash outflow) (www.sec.gov). The 2025 buybacks used roughly $173 million of the $200 million authorization (www.sec.gov). These repurchases reduced the outstanding share count (106.0 million shares as of Feb 2026 vs. ~113 million a year prior) and signal management’s confidence in the company’s value. However, Corcept’s buybacks also consumed cash that could have been allocated to pipeline development. The company notes that any share repurchases are discretionary and can be modified or suspended depending on other capital needs (www.sec.gov). Overall, while shareholders haven’t received dividends, Corcept has used buybacks as an alternative way to enhance shareholder value – effectively returning some cash to investors and potentially supporting the stock price.

Financial Position and Leverage

Balance Sheet Strength: Corcept’s financial position is solid and largely debt-free. According to its latest annual report, total assets were $836.7 million as of Dec 31, 2025, including a very large cash and investments reserve. Corcept held about $120.5 million in cash, $251.7 million in short-term marketable securities, and $160.3 million in long-term marketable securities at year-end 2025 (www.sec.gov). These holdings sum to over $532 million in liquid assets – a substantial war chest for a company of Corcept’s size. Liabilities, by contrast, were modest at $188.8 million (www.sec.gov). Crucially, none of these liabilities are interest-bearing debt: Corcept has no outstanding bank loans or bonds on its balance sheet (www.sec.gov). Current liabilities ( ~$166 million (www.sec.gov) ) consist mainly of accounts payable, accrued R&D expenses, and other accruals related to operations. Long-term liabilities (~$23 million) include lease liabilities and some deferred tax and rebate obligations (www.sec.gov) – but again, no long-term debt. This conservative capital structure means leverage is essentially zero, eliminating risks of interest burden or debt covenant issues.

Cash Flow and Coverage: With no debt, Corcept does not need to cover interest expenses – in fact, it earns interest. In 2025 the company generated $21.7 million in interest and other income, thanks to its large cash/investment holdings (www.sec.gov). This helped boost pre-tax income. Corcept’s operations are also cash-generative: net cash from operating activities was $190.4 million in 2025 (and positive each year recently), reflecting profitability and manageable working capital (www.sec.gov) (www.sec.gov). Management believes the existing cash on hand and ongoing cash flow are sufficient to fund planned R&D and operations for at least the next 12 months and beyond without needing to raise additional capital (www.sec.gov). This means Corcept can continue to invest in its pipeline (or fight legal battles) without the immediate pressure to dilute shareholders or incur debt. The strong liquidity buffer also provides some strategic flexibility – for example, Corcept could potentially deploy cash for an acquisition or partnership to augment its drug pipeline if organic development stalls. Overall, the balance sheet health is a bright spot: Corcept enters this challenging period (post-FDA rejection) with a robust cash cushion and no leverage, which lowers financial risk.

Revenue Growth and Profitability

Revenue Trend: Corcept has delivered steady revenue growth in recent years, driven entirely by sales of Korlym. In 2025, net product revenue was $761.4 million, a 13% increase from $675.0 million in 2024 (www.sec.gov). This continued growth is noteworthy given that a generic version of Korlym (mifepristone) became available in 2024. Corcept’s revenue nearly doubled from 2023 to 2025 – back in 2023, revenue was $482.4 million (www.sec.gov), so the company managed to expand its top line even as competition emerged. The 2024 jump (+40%) was partly because Corcept aggressively grew Korlym’s patient base and possibly took price increases ahead of generic entry. By 2025, growth slowed to 12–13%, but sales still rose despite generic competition. This resilience suggests that Corcept retained significant market share, potentially aided by its distribution strategy. (Corcept has utilized a single specialty pharmacy for Korlym distribution, and even launched an “authorized generic” of Korlym via its partner pharmacy when Teva’s generic entered (www.sec.gov). Selling an authorized generic allows Corcept to recapture some revenue at a lower price point, rather than lose the entire sale to Teva. Many patients likely continued to receive Korlym or its authorized generic through Corcept’s channels, mitigating revenue loss.)

However, looking forward, sustaining revenue growth will be challenging. With generics fully in the market (Teva received final approval and launched its generic in Jan 2024 (www.sec.gov)), 2026 could mark the first decline in Corcept’s sales as insurers and patients increasingly switch to cheaper alternatives. Corcept has not provided formal 2026 revenue guidance in the 10-K, but it acknowledged in risk disclosures that generic Korlym’s availability could cause revenue to decline materially (www.sec.gov). The pace of erosion will depend on how aggressively Teva (and potentially other generic manufacturers in the future) compete on price and access, and how effectively Corcept can leverage patient support programs or other means to maintain brand share.

Earnings and Margins: Corcept has been consistently profitable since the mid-2010s, a rarity among small biotechs. Yet its profitability has fluctuated as the company invests in growth. In 2025, net income was $99.7 million (GAAP), which is a 29% drop from the record $141.2 million net income in 2024 (www.sec.gov) (www.sec.gov). The decline was primarily due to higher operating expenses in 2025. Notably, Selling, General & Administrative (SG&A) expenses ballooned to $448.7 million in 2025 from $280.3 million in 2024 (www.sec.gov) – a 60%+ jump – as Corcept expanded its commercial team and marketing efforts, likely bracing for relacorilant’s launch and battling generic competition. Research & Development (R&D) expenses also ticked up to $254.9 million in 2025 (from $246.9M in 2024) as pipeline programs advanced (www.sec.gov). These cost increases far outpaced the 13% revenue growth, compressing operating profit. Operating income fell to $44.8 million in 2025, down from $137.0 million in 2024 (www.sec.gov).

Several one-time factors helped 2025’s net income not fall even further: Corcept recorded a $33.2 million income tax benefit in 2025 (www.sec.gov), likely due to the release of some valuation allowance on deferred tax assets given the company’s sustained profitability. This tax benefit actually boosted net profit above pre-tax profit (which was $66.5M). By contrast, 2024 had a $20.3 million tax expense. Excluding that tax accounting gain, the underlying pre-tax earnings drop from 2024 to 2025 was more severe than the GAAP net income decline.

Corcept’s net profit margin in 2025 was ~13% (on $761M revenue) – significantly lower than the ~21% margin in 2024. This reflects management’s decision to invest heavily in sales infrastructure and market access programs (e.g. patient support, distribution arrangements) ahead of relacorilant’s expected approval and to defend Korlym’s franchise. While such spending hit short-term earnings, it could have long-term benefits if relacorilant eventually gets approved or if it prolonged Korlym’s revenue durability. It’s also worth noting that Corcept’s gross margin on Korlym is extremely high (cost of goods was only $13.0M in 2025, ~1.7% of sales (www.sec.gov), as is typical for small-molecule drugs with premium pricing). Thus, the profitability levers for Corcept are mostly in SG&A and R&D control. If needed, Corcept could cut costs (for example, scaling back commercial spend) to preserve profit in the face of revenue declines – but that might also signal limited growth ambition.

Cash Flow: On a cash basis, Corcept remains strong. Operating cash flow in 2025 was around $190M (versus net income $100M), indicating significant non-cash expenses (like $84.5M of stock-based compensation in 2025 (www.sec.gov)) and some working capital benefit. The company used a large portion of this cash flow on share repurchases and still increased its cash/investments year-over-year. As of Dec 2025, Corcept’s cash and marketable securities ($532M) actually exceed its total liabilities (~$189M) by a wide margin (www.sec.gov) (www.sec.gov). This net cash position provides a cushion to weather income volatility.

Valuation and Market Metrics

Share Price Performance: Corcept’s stock has experienced dramatic swings reflecting clinical and legal developments. Over the 12 months through early 2026, CORT ranged from the low-$20s to over $70. The stock surged in 2025 as investors anticipated relacorilant’s approval and admired Corcept’s earnings growth. By December 2025, shares hit the $70+ level, giving the company a market capitalization around $7.4 billion. The subsequent FDA rejection news cut the stock in half to the mid-$30s (www.globenewswire.com). As of the time of this report, CORT trades roughly in the $35–40 per share range (market cap ~$3.7–$4.2 billion). The current price already factors in much of the bad news from the CRL, but it also implies the market is cautious on Corcept’s next steps.

Earnings Multiple: Using 2025’s net income of ~$100M, the stock at ~$37 is trading at a price-to-earnings (P/E) ratio in the ballpark of 37x–40x. Even using the higher 2024 earnings ($141M), the P/E would be ~26x at $37. These are relatively high multiples, indicating that the market is (still) pricing in growth or pipeline success rather than valuing Corcept like a no-growth pharma. For context, right after the CRL-induced crash, Corcept’s P/E spiked – at the $34–35 share price, one analysis pegged the trailing P/E near 45–50 (ycharts.com). (This is because earnings were suddenly expected to shrink going forward without relacorilant, so the “E” part of P/E became a smaller number.) Such a multiple is elevated compared to established biotech/pharma peers, especially considering the uncertainties ahead. It suggests there is still optimism that Corcept can rejuvenate growth (through relacorilant’s eventual approval or other pipeline advances). If growth instead stalls or reverses, there is downside risk of multiple contraction.

Sales Multiple and Peers: On a price-to-sales (P/S) basis, CORT trades at roughly 4.5–5 times annual revenue (using ~$800M forward sales estimate vs. ~$3.7B market cap). Large profitable pharma companies often trade at 4–6x sales with single-digit growth, whereas high-growth or specialty biotechs can trade much higher. In Corcept’s case, a ~5x sales multiple is not cheap given the threat of revenue decline from generics. But the valuation arguably reflects Corcept’s cash-rich balance sheet and pipeline optionality. Stripping out ~$5 per share in net cash, the enterprise value to sales is a bit lower (~4x). Comparable companies: It’s hard to find direct comps for Corcept. One could consider other rare-disease or endocrine-focused biotechs: for example, Xeris Biopharma (maker of Recorlev, another Cushing’s drug) is much smaller and not yet profitable. Or Horizon Therapeutics (with a thyroid eye disease drug) was acquired at ~8x sales, but Horizon had higher growth and a broader portfolio. Given Corcept’s unique situation (one commercial product, a profitable niche, and pipeline setback), the market seems to be valuing it somewhere between a stable specialty pharma and a growth biotech. Should relacorilant or another pipeline drug succeed, upside could be significant; if not, the stock could be re-valued closer to a mature one-product company (with a lower P/E and P/S).

Analyst Expectations: Before the FDA rejection, analysts projected relacorilant would add hundreds of millions in revenue within a few years, fueling ~20% annual growth (pro.thestreet.com). Those estimates have been cut or delayed. Now, consensus revenue for 2026 may be roughly flat to down (perhaps in the $700M range, as Korlym’s decline offsets any incremental growth). Earnings are expected to dip as well due to lower sales and continued R&D spend. If Corcept can maintain profitability and navigate to a second act (new product launch), the current valuation might prove justified. But at ~40x trailing earnings, the stock is not a classic bargain – it’s pricing in a rebound in the growth narrative. Investors thus must be confident in Corcept’s pipeline or expansion plans to buy at these levels.

Risks, Red Flags, and Open Questions

Corcept faces numerous risks at this juncture, spanning legal, competitive, and operational challenges. Below is a summary of key risk factors and red flags:

– Securities Fraud Allegations: The class action lawsuit (filed Feb 2026) claims Corcept misled investors about relacorilant. Specifically, it alleges that during 2024–2025, Corcept concealed the FDA’s serious concerns about relacorilant’s Phase 3 data, all while making positive public statements about the drug’s approval prospects (www.globenewswire.com) (www.globenewswire.com). According to the complaint, the FDA had cautioned Corcept that its trial design (the GRACE study) might be inadequate to demonstrate effectiveness – including explicit warnings that an NDA would face “significant issues” – but this was not disclosed (www.morningstar.com). When the truth emerged (via the CRL on Dec 30, 2025), the stock collapsed and shareholders suffered heavy losses (www.globenewswire.com). The lawsuit, led by an institutional shareholder, alleges violations of securities laws (Exchange Act Section 10(b) and Rule 10b-5) (www.sec.gov). Corcept denies the allegations and says it will vigorously defend itself (www.sec.gov), but the legal process could be protracted. If Corcept or its executives are found liable for fraud or misrepresentation, the company could face significant financial damages and reputational harm. At minimum, the suit shines a light on governance concerns – suggesting management might have been overly promotional about relacorilant despite regulatory pushback. Investors should monitor updates on this case (e.g. any evidence of intentional withholding of material FDA feedback).

– Regulatory and Pipeline Risk: The FDA’s rejection of relacorilant underscores regulatory risk in Corcept’s pipeline. The CRL means Corcept must undertake additional efforts (potentially a new clinical trial) to address the FDA’s requirements (www.sec.gov). This will cost time and money, with no guarantee of success. Every month relacorilant’s approval is delayed is a lost opportunity, especially as Korlym’s franchise erodes. Moreover, the lack of other late-stage assets heightens Corcept’s pipeline risk (www.trefis.com). If relacorilant ultimately fails to gain approval (or is delayed by years), Corcept would be solely dependent on aging Korlym and a handful of Phase 2 programs. The pipeline does include intriguing candidates (miricorilant for NASH, dazucorilant for ALS, etc.), but those will take several years (and substantial investment) to reach market, if they succeed at all. Pipeline development in biotech is inherently high-risk – many drugs in Corcept’s pipeline (spanning metabolic, oncologic, and neurological uses of cortisol modulation) could fail to show efficacy or safety. The concentration of R&D focus on a single mechanism (cortisol receptor antagonism) is another risk: a setback in one indication (e.g. relacorilant in Cushing’s) might portend difficulties in others. Regulatory risk extends beyond approvals – even if relacorilant eventually gets approved, labeling or usage could be restricted if efficacy is marginal. In short, the path to diversifying Corcept’s revenue is uncertain, and the timeline for new revenue streams is now pushed further out, testing investors’ patience.

– Concentration and Competition: Corcept derives virtually all its revenue from one product (Korlym) and one disease area. This concentration makes the company vulnerable. Generic competition for Korlym is already underway: Teva Pharmaceuticals launched a generic mifepristone in January 2024 after a court ruled that Teva’s product does not infringe Corcept’s patents (www.sec.gov). Corcept has fought to protect Korlym’s market share – including switching its exclusive specialty pharmacy partner and even providing an authorized generic – but over time, generics inevitably exert downward pressure on pricing and market share. In Corcept’s case, Korlym is a high-cost drug (list price reportedly in the tens of thousands of dollars annually per patient), so payers (insurers) have a strong incentive to favor cheaper generic options. Notably, a group of major insurers (including Aetna, Humana, HCSC, and Molina) filed an antitrust lawsuit in 2025 accusing Corcept of illegally maintaining a monopoly on Korlym even after generics became available (www.sec.gov). Their complaint mirrors Teva’s claims that Corcept engaged in anti-competitive practices – for example, by tying up distribution through specialty pharmacies (Corcept’s long-time pharmacy partner Optime/Curant dispensed Korlym and Corcept’s authorized generic, allegedly making it harder for Teva’s generic to gain traction) (www.sec.gov) (www.sec.gov). These allegations indicate that payers are aggressively pushing back on Corcept’s tactics to extend Korlym’s commercial life. The resolution of insurer and Teva antitrust cases (the Teva case is set for trial in March 2027 (www.sec.gov)) could impose injunctive relief or damages that further open the market to competition. For Corcept, the key question is how steeply Korlym sales will fall. Even with mitigation efforts, a significant erosion seems likely over the next 1–2 years due to generic substitution. This competitive risk is compounded by the fact that Korlym treats a relatively small patient population (Cushing’s syndrome is rare), so losing even a portion of patients to generics can translate to large percentage declines in sales. Also, new competing branded therapies for Cushing’s could emerge (for example, Recorlev by Xeris was approved in 2021). Corcept thus faces a multi-front competitive challenge: generic mifepristone, alternative medications for hypercortisolism, and payer cost-containment measures – all threatening its only stream of revenue.

– Legal and Regulatory Scrutiny: In addition to the securities class action, Corcept is entangled in multiple legal proceedings that pose financial and reputational risks. The U.S. Department of Justice (DOJ) has been investigating Corcept’s sales and marketing practices since at least November 2021, when the company received a federal subpoena (www.sec.gov). Authorities in the U.S. Attorney’s Office (New Jersey) are examining whether Corcept violated any laws in how it promoted Korlym, including its relationships with prescribing physicians and its handling of reimbursement and prior authorizations (www.sec.gov). While the inquiry was initially disclosed as fact-finding (with Corcept not named a defendant at that time) (www.sec.gov), such investigations can lead to enforcement actions or settlements (e.g. fines or a corporate integrity agreement) if wrongdoing is found (www.sec.gov). The status of this DOJ probe has not been fully updated in public filings, but it remains a hanging risk. Concurrently, Corcept is involved in intellectual property and antitrust litigation related to Korlym. The patent litigation against Teva over Korlym has effectively been lost – appeals were exhausted by Feb 2026, confirming Teva’s generic does not infringe Corcept’s key patents (www.sec.gov). More troubling perhaps is the antitrust suit: Teva filed an antitrust complaint in 2024 accusing Corcept and its (former) specialty pharmacy partner of colluding to delay generic entry (www.sec.gov). Although some claims were dismissed, Teva’s case is moving forward and a trial is scheduled for 2027 (www.sec.gov). The fact that large insurance companies followed with their own lawsuit (in California state court) alleging unfair business practices by Corcept (www.sec.gov) shows that multiple stakeholders believe Corcept’s conduct around Korlym’s distribution and payor agreements may have been unlawful. If Corcept loses these cases, financial damages or settlements could be significant – Teva and the insurers would likely seek compensation for higher drug costs attributed to Corcept’s actions. Beyond monetary impact, these legal battles highlight red flags in Corcept’s business practices. The alleged use of exclusive specialty pharmacy deals, aggressive physician payments (a focus of the DOJ probe), and other tactics suggest Corcept operated close to ethical and legal lines to maximize Korlym sales. Investors should be aware that the outcomes of these investigations and suits (which may take years) could further impair Corcept’s finances and reputation.

– Reliance on One Product & Patent Expiry: Corcept’s business model for the past decade has centered on one niche drug. Korlym’s orphan drug exclusivity has expired, and its key patents have either been invalidated or will expire in the early 2030s (www.sec.gov) (www.sec.gov). In fact, Teva’s success in court essentially opened the door for generic Korlym well before 2030. Corcept’s remaining Korlym patents (such as method-of-use patents) did not prevent generic entry; at this point, it appears Korlym will face full generic competition going forward. The risk of revenue contraction is high – Korlym could follow the typical trajectory of a small-molecule drug losing exclusivity, where sales drop sharply (50%+ decline within a year or two is not uncommon in pharma). Corcept’s attempts to replace Korlym with relacorilant hit a major setback, so the company might see a gap with no new product to offset the decline. This one-product reliance also means any new safety or regulatory issue with Korlym would be devastating. (Korlym is basically the drug mifepristone, which is well-studied, but its use in Cushing’s requires careful monitoring due to potential side effects. Corcept must manage these risks and has responsibility for post-market safety reporting; any hint of an unexpected safety problem could curtail usage.) Additionally, health policy changes could impact Korlym’s pricing power. The U.S. Inflation Reduction Act (2022) empowers Medicare to negotiate prices of certain expensive drugs once they’ve been on the market a number of years. It’s conceivable that Korlym could become subject to such price negotiations or rebates, given its cost and Medicare’s desire to contain spending (www.sec.gov). Corcept even flagged in its filings that Medicare pricing reforms and a 2025 federal law (informally dubbed the “One Big Beautiful Bill Act”) – which reduced some healthcare program funding – could reduce patients’ access or affordability of its drug (www.sec.gov) (www.sec.gov). In summary, Corcept’s core business has significant headwinds: patent expiry, generic competition, and external pricing pressure all threaten the longevity of Korlym’s cash flows.

– Open Questions & Outlook: A number of open questions will determine Corcept’s trajectory from here. First, can Corcept salvage relacorilant? The company will need to design a new trial or data package to convince the FDA of relacorilant’s effectiveness in Cushing’s syndrome. What that trial looks like – e.g. a larger sample size, different endpoints, longer duration? – and how long it will take are critical unknowns. Investors likely won’t get an approval until 2027 or beyond, assuming success on a second attempt. If relacorilant ultimately gains approval, can it still fulfill its blockbuster potential (or has the delay allowed competitors or generics to fill the void)? Second, how will Korlym sales decay over the next 1-2 years? Will Corcept’s authorized generic and niche strategy allow a slower glide path (say, a 20–30% annual decline), or will sales rapidly erode (50%+ decline) as payers push substitution? Early signs in 2024–25 were that Corcept managed to hold up well, but the real test comes after the Federal Circuit’s February 2026 decision that firmly ended Corcept’s patent defense (www.sec.gov). With no remaining legal barriers, generics could become more aggressive. Third, can Corcept’s other pipeline programs advance fast enough to matter? The Phase 2 trial of miricorilant in liver disease (MASH) will read out results – positive data could provide a new avenue (NASH is a large unmet need), but even in best case a Phase 3 and approval would take years (www.sec.gov) (www.sec.gov). The dazucorilant program in ALS is high-risk/high-reward; ALS trials are difficult, and success is far from assured. Corcept may also explore external opportunities: its strong cash position could be used for acquisitions or licensing of other late-stage assets to diversify the portfolio. This is a strategic question – will Corcept remain focused solely on its cortisol-modulator niche, or will it deploy cash to acquire a product in a different area to generate revenue? Finally, there is the question of leadership and governance. The flurry of legal troubles and the major R&D setback raise scrutiny on management’s decision-making. Investors will be watching how management navigates the crisis – for instance, will they maintain heavy spending (burning cash) or start scaling back costs to preserve profitability? And can they rebuild credibility with both regulators and shareholders? These open questions mean the range of outcomes for Corcept’s stock is wide. In a bullish scenario, relacorilant eventually gets approved and new indications (or an acquisition) drive renewed growth, making Corcept a successful turnaround story. In a bearish scenario, Korlym sales crumble faster than new products emerge, and ongoing legal issues drain resources – in that case, Corcept could see its valuation compress significantly.

Bottom Line: Corcept Therapeutics finds itself at a crossroads. The class action lawsuit and steep stock drop highlight the market’s disappointment and the potential red flags in management’s transparency (www.globenewswire.com) (www.globenewswire.com). From an equity analysis perspective, the company still has some fundamental strengths – a profitable core product (for now), substantial cash reserves, and a focused R&D pipeline – but these are counter-balanced by significant risks – concentrated revenue with looming generic erosion, a delayed pipeline, and multiple legal battles. Investors considering CORT should carefully weigh these factors. In the coming quarters, pay close attention to Korlym’s sales trend (an indicator of how hard generics and payers are biting), any communications from the FDA/Corcept on relacorilant’s next steps, and updates on the legal front (settlements or judgments could surprise). Corcept’s story is evolving, and the April 21, 2026 class action deadline is a reminder of the serious allegations regarding its past conduct (www.globenewswire.com). Going forward, restoring trust – with regulators, patients, and investors – will be as critical for Corcept as any single financial metric. The situation indeed merits an “alert” for shareholders: CORT is a high-risk, high-uncertainty stock at this point, with outcomes ranging from rebound to further reversal, depending on how those open questions get resolved. (www.trefis.com) (www.sec.gov)

For informational purposes only; not investment advice.